- Sales increased by 7% to DKK 18,479 million in the first nine months of 2002 compared to the first nine months of 2001. Sales increased by 10% measured in local currencies.
- Diabetes care sales increased by 7% to DKK 12,967 million.
- Haemostasis management sales increased by 17% to DKK 2,635 million.
- Growth hormone therapy sales increased by 1% to DKK 1,553 million.
- Hormone replacement therapy sales decreased by 3% to DKK 1,007 million.
- For the third quarter of 2002 alone sales increased by 8% to DKK 6,445 million compared to the third quarter last year. Sales increased by 13% measured in local currencies.
- Operating profit increased by 6% to DKK 4,374 million in the first nine months of 2002. Operating profit increased by 9% to DKK 1,518 million in the third quarter alone. Adjusted for non-recurring items in the third quarter of 2001, operating profit grew by 20% in the third quarter of 2002 compared to the same period in 2001.
- Lars Rebien Sørensen, president & CEO, said, "The strong performance in the third quarter confirms that we are on track to deliver our expectations for the full year, even though the currency environment has become increasingly negative for Novo Nordisk."
- Novo Nordisk reaffirms its expectations of growing operating profit by 5-10% in 2002, although towards the lower end of the range if exchange rates do not improve from present levels.
- Preliminary plans for 2003 indicate that growth in operating profit in local currencies will live up to the long-term objective of growing operating profit by 15%. However, if the present currency exchange rates prevail throughout the full year of 2003, the growth in operating profit for 2003 measured in Danish kroner will be reduced by around 5 percentage points.
Financial statement for the first nine months of 2002
| Quelle: Novo Nordisk A/S